BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Krazati (Adagrasib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Krazati (Adagrasib)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06026410-2025@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Krazati (Adagrasib): Phase 1 readout est. (NCT06026410)
DESCRIPTION:Krazati (Adagrasib)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumor
 s\nEstimated primary completion: January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/adagrasib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06026410
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06248606-2025@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:Krazati (Adagrasib): Phase 2 readout est. (NCT06248606)
DESCRIPTION:Krazati (Adagrasib)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC 
 With Untreated Brain Metastases\nEstimated primary completion: 25 February
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/adagrasib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06248606
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722327-2025@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Krazati (Adagrasib): Phase 1 readout est. (NCT05722327)
DESCRIPTION:Krazati (Adagrasib)\, phase 1.\nStudy: Phase I Trial of Adagras
 ib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With
  Colorectal Cancer\nEstimated primary completion: 30 September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/adagrasib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05722327
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764771-2025@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Krazati (Adagrasib): Phase 1 readout est. (NCT06764771)
DESCRIPTION:Krazati (Adagrasib)\, phase 1.\nStudy: A Study of BMS-986488 as
  Monotherapy and Combination Therapy in Participants With Advanced Maligna
 nt Tumors\nEstimated primary completion: 15 October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adagrasib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06764771
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382726-2025@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271224
DTEND;VALUE=DATE:20271225
SUMMARY:Krazati (Adagrasib): Phase 1 readout est. (NCT07382726)
DESCRIPTION:Krazati (Adagrasib)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The I
 ZA-A Trial\nEstimated primary completion: 24 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/adagrasib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07382726
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415031-2025@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Krazati (Adagrasib): Phase 2 readout est. (NCT07415031)
DESCRIPTION:Krazati (Adagrasib)\, phase 2.\nStudy: A Solid Tumor Study for 
 Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studi
 es\nEstimated primary completion: 16 February 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/adagrasib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07415031
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04613596-2025@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Krazati (Adagrasib): Phase 2/3 readout est. (NCT04613596)
DESCRIPTION:Krazati (Adagrasib)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pemb
 rolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With
  a KRAS G12C Mutation KRYSTAL-7\nEstimated primary completion: 31 October 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/adagrasib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04613596
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412198-2025@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Krazati (Adagrasib): Phase 1/2 readout est. (NCT06412198)
DESCRIPTION:Krazati (Adagrasib)\, phase 1/2.\nStudy: A Multicenter Phase 1b
 /2 Study of Adagrasib\, Cetuximab\, and Cemiplimab for Metastatic Colorect
 al Cancer Harboring KRAS G12C Mutations\nEstimated primary completion: 1 M
 arch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adagrasib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0641
 2198
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06875310-2025@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Krazati (Adagrasib): Phase 3 readout est. (NCT06875310)
DESCRIPTION:Krazati (Adagrasib)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo
  Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untr
 eated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRY
 STAL-4)\nEstimated primary completion: 7 September 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/adagrasib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06875310
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
